Prostate cancer patients may soon be able to receive abiraterone on the NHS after the National Institute for Clinical Excellence (Nice) recommended it for wider use.
The drug can help to prolong life for patients whose tumours have returned after chemotherapy, but Nice had previously rejected the drug for NHS use due to its cost, meaning abiraterone was only available via the Cancer Drugs Fund in England.
Now, maker Janssen has offered new information to Nice and the authority has sanctioned the drug's use on the NHS.
Dr Harpal Kumar, chief executive of Cancer Research UK, said: "This is wonderful news for patients with advanced prostate cancer and, in part, this U-turn is down to the public's disappointment at the initial refusal."
NHS bodies will now make funding decisions on a local basis until Nice draws up its final guidelines for the drug.
According to Cancer Research UK, prostate cancer is the most common form of the disease among British men